基于MRI的前列腺癌HIFU术后监测:PI-FAB评分的阅片者间一致性与诊断效能
回顾性单中心研究纳入73例接受局灶性HIFU治疗的前列腺癌患者,于术后6、12、36个月随访mpMRI并以后续前列腺活检为参考,由两位不同经验阅片者应用PI-FAB评分。评分阅片者间一致性为实质性至几乎完美(AC1 0.80–0.95),排除术区内残留或复发癌的特异度高、阴性预测值高,敏感度与阳性预测值相对较低且两位阅片者间差异明显。
要点
- PI-FAB评分阅片者间一致性为实质性至几乎完美(AC1 0.80–0.95)。
- 排除术区内残留或复发癌特异度高(阅片者1 90–98%,阅片者2 87–98%)。
- 阴性预测值高(阅片者1 91–100%,阅片者2 88–97%),敏感度较低且两位阅片者间差异明显。
核心结论
- PI-FAB评分用于HIFU术后mpMRI监测具有实质性至几乎完美的阅片者间一致性,在排除术区内残留或复发前列腺癌方面尤其有效,其应用可能改善治疗后患者管理,体现其作为前列腺局灶消融术后无创MRI监测方法的价值。
研究设计与样本
- 回顾性、经IRB批准的单中心研究,纳入73例接受局灶性HIFU治疗并完成随访mpMRI及后续前列腺活检的男性患者;两位不同经验水平的放射科医师对HIFU术后6、12、36个月的随访MRI应用PI-FAB评分,以随后的前列腺活检组织病理结果为参考标准。
诊断标准与关键数值
- PI-FAB评分阅片者间一致性AC1为0.80–0.95;排除术区内残留或复发前列腺癌的特异度阅片者1为90–98%、阅片者2为87–98%,阴性预测值阅片者1为91–100%、阅片者2为88–97%,敏感度阅片者1≥43%、阅片者2≥14%,阳性预测值阅片者1≥33%、阅片者2≥14%。
临床应用与阅片要点
- 作者认为PI-FAB评分可作为HIFU术后基于mpMRI的无创监测工具,尤其用于排除术区内残留或复发前列腺癌;两位阅片者间敏感度与阳性预测值差异明显,提示放射科医师经验可能影响评分表现。
局限性
- 原文为回顾性、单中心研究。
- 敏感度(阅片者1≥43%,阅片者2≥14%)与阳性预测值(阅片者1≥33%,阅片者2≥14%)相对较低,且两位阅片者间差异明显,提示放射科医师经验可能存在影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate inter-reader agreement, and diagnostic performance of the Prostate Imaging after Focal Ablation (PI-FAB) score applied to multiparametric MRI (mpMRI) in patients who underwent focal high-intensity focused ultrasound (HIFU) therapy for localized prostate cancer.
METHODS: In this retrospective, IRB-approved, single-center study, 73 men, who underwent focal HIFU treatment and received follow-up mpMRIs with subsequent prostate biopsies, were included. The PI-FAB score was applied to follow-up MRIs at 6, 12, and 36 months post-HIFU by two radiologists with different experience levels. Inter-reader agreement was assessed using Gwet's AC1, and the diagnostic performance of the PI-FAB score was assessed in relation to histopathologic results of subsequent prostate biopsies for each reader.
RESULTS: PI-FAB scores showed substantial to almost perfect inter-reader agreement (AC1: 0.80-0.95) and demonstrated high specificity (Reader 1: 90-98 %, Reader 2: 87-98 %) and NPVs (Reader 1: 91-100 %, Reader 2: 88-97 %) in ruling out residual or recurrent in-field prostate cancer post-HIFU. Sensitivity (Reader 1: ≥43 %, Reader 2: ≥14 %) and PPVs (Reader 1: ≥33 %, Reader 2: ≥14 %) were mostly relatively lower, with notable disparities between the two readers, indicating the potential influence of radiologist experience.
CONCLUSIONS: The PI-FAB score provides a consistent and reliable tool for post-HIFU monitoring of prostate cancer using mpMRI. It demonstrates substantial to almost perfect inter-reader agreement and is particularly effective in excluding in-field residual or recurrent prostate cancer post-HIFU treatment. Its application can potentially enhance post-treatment patient care, emphasizing its value as a non-invasive MRI-based monitoring approach after focal ablative therapy of the prostate.
引用
- Pausch AM, Elsner C, Rupp NJ, et al. MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score. Eur J Radiol. 2024. PMID: 38615502. doi:10.1016/j.ejrad.2024.111463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。